CAR-MAIT Cells for T-Cell Lymphoma Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies are limited in treating T-cell malignancies due to autologous transfusion limitations, on-target/off-tumor toxicity, and variability in patient T-cell function, and existing methods for expanding MAIT cells require allogenic feeder cells, making large-scale production and allogeneic adoptive transfer challenging.
Innovation Solution
Development of novel methods for stimulating and isolating highly pure MAIT cells using genetic constructs like CART4 and CARTVb7.1, which encode chimeric antigen receptors (CARs) targeting CD4 or TCR-Vbeta 7.1, allowing for the creation of CAR-MAIT cells that can be used for allogeneic therapy, and a process involving MACS and FACS for purification and expansion of MAIT cells without allogenic feeder cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CAR-T therapy is used for T-cell malignancies, then autologous transfusion can be performed, but graft-versus-host disease occurs and limits further application
Solution Approach 1:
The patent uses MAIT cells as an intermediary cell type between conventional CAR-T cells and the patient's immune system. These MAIT cells are engineered to express CARs targeting T-cell malignancies but lack the ability to cause severe GVHD, thus mediating the therapeutic effect while reducing harmful side effects
Solution Approach 2:
The patent creates a copy of the desired therapeutic function by engineering MAIT cells to express chimeric antigen receptors (CARs) that target T-cell malignancies. Instead of using patient's own T cells (autologous), the therapy uses engineered MAIT cells that replicate the tumor-targeting capability without the associated risks
2Reliability
If pan-T cell markers are targeted by monoclonal antibodies for T lymphoma treatment, then partial regression is achieved, but only partial response is obtained
Solution Approach 1:
The patent applies local quality by engineering MAIT cells to express CARs with specific affinity and specificity for T-cell malignancy markers. This localized enhancement of targeting capability at the cell surface allows for more effective and selective tumor regression compared to systemic monoclonal antibody therapy
3Productivity
If existing MAIT cell expansion methods using allogenic feeder cells are used, then MAIT cells can be expanded, but large-scale production and allogeneic adoptive transfer become challenging
Solution Approach 1:
The patent extracts the essential function of MAIT cell expansion by identifying and utilizing specific cytokine signals and activation pathways that can drive proliferation without requiring allogenic feeder cells. This extraction of the core expansion mechanism simplifies the production process
Solution Approach 2:
The patent enables MAIT cells to serve themselves by providing autonomous expansion capability through engineered cytokine receptors and activation pathways. The cells can proliferate in response to defined cytokine stimuli without needing external feeder cell support, making the system self-sufficient
4Ease of operation
If conventional CAR-T therapy is used for solid tumors, then treatment can be administered, but tumor infiltration is inadequate and efficacy is low
Solution Approach 1:
The patent applies dynamics by engineering MAIT cells with enhanced migratory and infiltrative capabilities. The cells are designed to dynamically respond to tumor microenvironment cues and actively migrate into solid tumors, rather than remaining static in the bloodstream like conventional CAR-T cells
Data Source
AI summary
The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating, and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention is also concerned with methods for expansion of MAIT cells in vitro.